Benitec Biopharma Inc

BNTCNASDAQ · USD
8.54USD0.00 (-5.54%)
315

Benitec Biopharma Inc (BNTC) Covered Calls

Benitec Biopharma Inc trades in the Biotechnology industry with an IV Rank of 73.81%, high versus the past year. BNTC's highest covered call setup is the $15.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 65.93% out of the money with 154 days to expiration, a 67.04% return until expiration, and a 158.88% theoretical annualized return. Across the setups shown, annualized returns run from 43.52% to 158.88% at strikes between $10.00 and $15.00, with 154 to 154 days to expiration, as of Nov 13, 2026.

Read more

Running BNTC covered calls helps you generate income from Benitec Biopharma Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BNTC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BNTC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BNTC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BNTC covered call is worth writing.

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

2027-04-1615415.0065.930.104.90606.0067.04158.88-1.11+0.5414.80
2027-04-1615412.5038.270.104.90356.0039.3893.34-1.11+0.5624.80
2027-04-1615410.0010.620.704.90166.0018.3643.52-7.74+0.6314.20

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank73.81% High
  • Market cap (M$)298
  • 52 weeks high-40.65%
  • 52 weeks low8.38%
  • Analyst recommendationStrong Buy
    1.25
  • Target price$23.75
    178.10% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2027-02-11
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.13
  • EPS growth next 5 years-12.98%

As of Nov 13, 2026